The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology—When and Why?

The fundamental pathophysiology of malignancies is dysregulation of the signalling pathways. Protein tyrosine kinases (PTKs) are among the enzymes which, if mutated, play a critical role in carcinogenesis. The best-studied rearrangement, which enhances PTK activity and causes atypical proliferation,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Agnieszka Kaczmarska, Patrycja Śliwa, Monika Lejman, Joanna Zawitkowska
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	tyrosine kinase inhibitors TKIs paediatric oncology Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/fddfddc3f7d44f13a4fee49601feba77
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fddfddc3f7d44f13a4fee49601feba77
record_format	dspace
spelling	oai:doaj.org-article:fddfddc3f7d44f13a4fee49601feba772021-11-11T17:28:41ZThe Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology—When and Why?10.3390/ijms2221120891422-00671661-6596https://doaj.org/article/fddfddc3f7d44f13a4fee49601feba772021-11-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/21/12089https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067The fundamental pathophysiology of malignancies is dysregulation of the signalling pathways. Protein tyrosine kinases (PTKs) are among the enzymes which, if mutated, play a critical role in carcinogenesis. The best-studied rearrangement, which enhances PTK activity and causes atypical proliferation, is <i>BCR-ABL1</i>. Abnormal expression of PTKs has proven to play a significant role in the development of various malignancies, such as chronic myelogenous leukaemia, brain tumours, neuroblastoma, and gastrointestinal stromal tumours. The use of tyrosine kinase inhibitors (TKIs) is an outstanding example of successful target therapy. TKIs have been effectively applied in the adult oncology setting, but there is a need to establish TKIs’ importance in paediatric patients. Many years of research have allowed a significant improvement in the outcome of childhood cancers. However, there are still groups of patients who have a poor prognosis, where the intensification of chemotherapy could even cause death. TKIs are designed to target specific PTKs, which lead to the limitation of severe adverse effects and increase overall survival. These advances will hopefully allow new therapeutic approaches in paediatric haemato-oncology to emerge. In this review, we present an analysis of the current data on tyrosine kinase inhibitors in childhood cancers.Agnieszka KaczmarskaPatrycja ŚliwaMonika LejmanJoanna ZawitkowskaMDPI AGarticletyrosine kinase inhibitorsTKIspaediatric oncologyBiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 12089, p 12089 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	tyrosine kinase inhibitors TKIs paediatric oncology Biology (General) QH301-705.5 Chemistry QD1-999
spellingShingle	tyrosine kinase inhibitors TKIs paediatric oncology Biology (General) QH301-705.5 Chemistry QD1-999 Agnieszka Kaczmarska Patrycja Śliwa Monika Lejman Joanna Zawitkowska The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology—When and Why?
description	The fundamental pathophysiology of malignancies is dysregulation of the signalling pathways. Protein tyrosine kinases (PTKs) are among the enzymes which, if mutated, play a critical role in carcinogenesis. The best-studied rearrangement, which enhances PTK activity and causes atypical proliferation, is <i>BCR-ABL1</i>. Abnormal expression of PTKs has proven to play a significant role in the development of various malignancies, such as chronic myelogenous leukaemia, brain tumours, neuroblastoma, and gastrointestinal stromal tumours. The use of tyrosine kinase inhibitors (TKIs) is an outstanding example of successful target therapy. TKIs have been effectively applied in the adult oncology setting, but there is a need to establish TKIs’ importance in paediatric patients. Many years of research have allowed a significant improvement in the outcome of childhood cancers. However, there are still groups of patients who have a poor prognosis, where the intensification of chemotherapy could even cause death. TKIs are designed to target specific PTKs, which lead to the limitation of severe adverse effects and increase overall survival. These advances will hopefully allow new therapeutic approaches in paediatric haemato-oncology to emerge. In this review, we present an analysis of the current data on tyrosine kinase inhibitors in childhood cancers.
format	article
author	Agnieszka Kaczmarska Patrycja Śliwa Monika Lejman Joanna Zawitkowska
author_facet	Agnieszka Kaczmarska Patrycja Śliwa Monika Lejman Joanna Zawitkowska
author_sort	Agnieszka Kaczmarska
title	The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology—When and Why?
title_short	The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology—When and Why?
title_full	The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology—When and Why?
title_fullStr	The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology—When and Why?
title_full_unstemmed	The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology—When and Why?
title_sort	use of inhibitors of tyrosine kinase in paediatric haemato-oncology—when and why?
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/fddfddc3f7d44f13a4fee49601feba77
work_keys_str_mv	AT agnieszkakaczmarska theuseofinhibitorsoftyrosinekinaseinpaediatrichaematooncologywhenandwhy AT patrycjasliwa theuseofinhibitorsoftyrosinekinaseinpaediatrichaematooncologywhenandwhy AT monikalejman theuseofinhibitorsoftyrosinekinaseinpaediatrichaematooncologywhenandwhy AT joannazawitkowska theuseofinhibitorsoftyrosinekinaseinpaediatrichaematooncologywhenandwhy AT agnieszkakaczmarska useofinhibitorsoftyrosinekinaseinpaediatrichaematooncologywhenandwhy AT patrycjasliwa useofinhibitorsoftyrosinekinaseinpaediatrichaematooncologywhenandwhy AT monikalejman useofinhibitorsoftyrosinekinaseinpaediatrichaematooncologywhenandwhy AT joannazawitkowska useofinhibitorsoftyrosinekinaseinpaediatrichaematooncologywhenandwhy
_version_	1718432098517254144

The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology—When and Why?

Ejemplares similares